Impacts of glycoprotein IIb/IIIa inhibition on QT dispersion after successful percutaneous coronary intervention

Angiology

Volumn 57, Issue 3, 2006, Pages 273-281

  Okmen, Ertan ^a,b   Sanli, Arda ^a   Uyarel, Huseyin ^a   Dayi, Sennur ^a   Tartan, Zeynep ^a   Cam, Nese ^a  

^a DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CREATINE KINASE MB; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TICLOPIDINE; TIROFIBAN; TROPONIN I; DRUG DERIVATIVE; FIBRINOLYTIC AGENT; TYROSINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; ELECTROCARDIOGRAM; FEMALE; GUIDE WIRE; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; QT DISPERSION; RANDOMIZED CONTROLLED TRIAL; TRANSLUMINAL CORONARY ANGIOPLASTY; BLOOD; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; ECHOCARDIOGRAPHY; HEART ARRHYTHMIA; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; POSTOPERATIVE COMPLICATION; STENT; TIME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ARRHYTHMIA; CREATINE KINASE, MB FORM; DRUG ADMINISTRATION SCHEDULE; ECHOCARDIOGRAPHY; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POSTOPERATIVE COMPLICATIONS; STENTS; TIME FACTORS; TROPONIN I; TYROSINE;

EID: 33745515805     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970605700303     Document Type: Article

References (27)

1. Day CP, McComb JM, Campbell RWF: QT dispersion: An indication of arrhythmia risk in patients with long QT intervals. Br Heart J 63:342-344, 1990.
2. Day CP, McComb JM, Campbell RWF: QT dispersion in sinus beats and ventricular extrasystoles in normal heart. Br Heart J 67:39-41, 1992.
3. Barr CS, Naas A, Freeman M, et al: QT dispersion and sudden unexpected death in chronic heart failure. Lancet 343:327-329, 1994.
4. Fei L, Goldman JH, Prasad K, et al: QT dispersion and RR variations on 12-lead ECGs in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy. Eur Heart J 17:258-263, 1996.
5. Perkiömäki JS, Koistinen MJ, Yli-Mayry S, et al: Dispersion of the QT interval in patients with and without susceptibility to ventricular tachyarrhythmias after previous myocardial infarction. J Am Coll Cardiol 26:174-179, 1995.
6. Glancy JM, Garrat CJ, Woods KL, et al: QT dispersion and mortality after myocardial infarction. Lancet 345:945-948, 1995.
7. Kelly RF, Parillo JE, Hollenberg SM: Effect of coronary angioplasty on QT dispersion. Am Heart J 134:399-405, 1997.
8. Yesilbursa D, Serdar A, Aydinlar A: Effect of successful coronary angioplasty and stent implantation on QT dispersion. Coron Artery Dis 10:335-337, 1999.
9. Ashikaga T, Nishizaki M, Arita M, et al: Increased QTc dispersion predicts lethal ventricular arrhythmias complicating coronary angioplasty. Am J Cardiol 82:814-8166, A10, 1998.
10. Badimon L, Badimon JJ, Galvez A, et al: Influence of arterial wall damage and wall shear rate on platelet deposition: Ex vivo study in a swine model. Arteriosclerosis 6:312-320, 1986.
11. Wilentz JR, Sanborn TA, Haudenschild CC, et al: Platelet accumulation in experimental angioplasty: Time course and relation to cardiovascular injury. Circulation 75:636-642, 1987.
12. Phillips DR, Charo IF, Parise LV, et al: The platelet membrane glycoprotein IIb-IIIa complex. Blood 71:831-843, 1988.
13. Coller BS: Platelets and thrombolytic therapy. N Engl J Med 322:33-42, 1990.
14. EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330:956-961, 1994.
15. Ellis SG, Lincoff AM, Miller D, et al, for the EPIC and EPILOG Investigators: Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology: Evaluation of 7E3 for the prevention of ischemic complications: Evaluation of PTCA to improve long-term outcome with abciximab GP IIb/IIIa receptor blockade. J Am Coll Cardiol 32:1619-623, 1998.
16. EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336:1689-1696, 1997.
17. CAPTURE Investigators: Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina. Lancet 349:1429-1435, 1997.
18. EPISTENT Investigators: Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade: Evaluation of platelet IIb/IIIa inhibitor for stenting. Lancet 352:87-92, 1998.
19. Lincoff AM, Califf RM, Moliterno DJ, et al: Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors: Evaluation of platelet IIb/IIIa inhibition in stenting investigators. N Engl J Med 341:319-327, 1999.
20. Neumann FJ, Schomig A: Glycoprotein IIb/IIIa receptor blockade with coronary stent placement. Semin Interv Cardiol 3:81-90, 1998.
21. Ryan TJ, Bauman WB, Kennedy JW, et al: Guidelines for percutaneous transluminal coronary angioplasty: A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation 78:486-502, 1988.
22. Smith SC Jr, Dove JT, Jacobs AK, et al: ACC/ AHA guidelines for percutaneous coronary intervention: A report of American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary angioplasty). J Am Coll Cardiol 37:2239i-lxvi, 2001.
23. Zareba W, Moss AJ, la Cessie S: Dispersion of ventricular repolarization and arrhythmic death in coronary artery disease. Am J Cardiol 74:550-553, 1994.
24. Sporton SC, Taggart P, Sutton PM, et al: Acute ischemia: A dynamic influence on QT dispersion. Lancet 349:306-309, 1997.
25. Moreno FL, Vilaneuva T, Karagunis LA, et al, for TEAM-2: Reduction in QT interval dispersion by successful thrombolytic therapy in acute myocardial infarction. Circulation 90:94-100, 1994.
26. Ali A, Malik FS, Dinshaw H, et al: Reduction in QT dispersion with rheolytic thrombectomy in acute myocardial infarction: Evidence of electrical stability with reperfusion therapy. Cathet Cardiovasc Interv 52:56-58, 2001.
27. Kong DF, Califf RM, Miller DP, et al: Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 98:2829-2835, 1998.